Finsbury Emerging Biotechnology Tst
31 January 2006
FINSBURY EMERGING BIOTECHNOLOGY TRUST PLC
NET ASSET VALUE
The estimated unaudited net asset value, calculated in accordance with the
guidelines of the Association of Investment Trust Companies, for Finsbury
Emerging Biotechnology Trust PLC at the close of business on 30 January 2006 was
122.86p (ex income).
The estimated NAV above includes the Company's interest in the Merlin Fund LP
('Merlin'), which holds listed investments, cash and unlisted investments. The
Company's pro rata share of unquoted securities in Merlin represents 3.0% of the
Company's estimated net asset value. The pro rata share of the listed
securities and cash in Merlin represent 3.9% and 0.3% respectively of the
Company's estimated NAV. The Company also holds unquoted securities
representing a further 2.1% of the Company's estimated net asset value.
For and on behalf of the Board
Close Finsbury Asset Management Limited
Secretary
31 January 2006
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.